)
Aurora Spine (ASG) investor relations material
Aurora Spine Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved record annual and Q4 2025 revenue, with Q4 marking the first $5 million revenue quarter in company history and fiscal 2025 revenue reaching $18.4 million, up 4.6% year-over-year.
Strong momentum attributed to expanded internal sales force, successful proprietary product launches (ZIP, SiLO, DEXA-L), and the launch of Aurora Biologics.
Launched DEXA-L, the first bone density-matched lumbar implant, and prepared for DEXA-C and other product extensions in 2026.
Two new product extensions planned for 2026, including a disposable kit for SI joint pain and further DEXA-enabled products.
Expanded sales and marketing team, with new hires covering previously uncovered territories and increased advanced training for physicians.
Financial highlights
Q4 2025 revenue reached $5.02 million, up 14% sequentially and 7% year-over-year; fiscal 2025 revenue was $18.4 million, up from $17.6 million in 2024.
Gross profit margin improved to 62.4% in Q4 2025 from 57.8% in Q4 2024; fiscal 2025 gross margin was 61%.
Q4 2025 net loss narrowed to $41,000 from $653,000 in Q4 2024; fiscal 2025 net loss was $731,000, improved from $1 million in 2024.
EBITDAC for Q4 2025 was $301,000, up from $165,000 in Q3 and a loss of $320,000 in Q4 2024; fiscal 2025 EBITDAC was $587,000, up 108% from 2024.
Ended the year with nearly $99,000 in cash and improved accounts receivable collections, including $202 million collected in December.
Outlook and guidance
Anticipates continued sales momentum and growth in 2026, with seasonality expected but a stronger start than the previous year.
Expects new product launches and expanded sales force to drive further revenue growth.
Focused on achieving cash flow positivity and leveraging new biologic and DEXA product lines.
- Record 2025 revenues and margins driven by proprietary spinal implants and pain market focus.ASG
Investor presentation23 Mar 2026 - Revenue up 14.3% to $4.1M, gross margin 62.4%, and EBITDAC positive for fourth quarter.ASG
Q2 202423 Jan 2026 - Record revenue and first profitable quarter driven by strong implant sales and margin gains.ASG
Q3 202418 Jan 2026 - 2026 will see major product launches, sales expansion, and a push for profitability and revenue growth.ASG
2nd Annual Lytham Partners Healthcare Investor Summit15 Jan 2026 - Strong Q3 2024 growth, innovative spine products, and NASDAQ uplisting targeted for 2026.ASG
Planet MicroCap Showcase: VEGAS 202524 Nov 2025 - 2024 revenue up 21% to $17.6M, margin gains, and first positive EBITDA/EBITDAC achieved.ASG
Q4 202424 Nov 2025 - Record October sales and new product launches offset a 7.1% Q3 revenue decline.ASG
Q3 202519 Nov 2025 - Record Q1 revenue and new product launches set the stage for 20%+ annual growth in 2025.ASG
Q1 202513 Nov 2025 - Hybrid sales expansion and new product launches set stage for accelerated growth in 2025.ASG
Lytham Partners Spring 2025 Investor Conference10 Nov 2025
Next Aurora Spine earnings date
Next Aurora Spine earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)